» Articles » PMID: 18849077

Btk Regulates Localization, in Vivo Activation, and Class Switching of Anti-DNA B Cells

Overview
Journal Mol Immunol
Date 2008 Oct 14
PMID 18849077
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The autoimmune disease systemic lupus erythematosus (SLE) is characterized by loss of tolerance to nuclear antigens such as chromatin, DNA, and RNA. This focused autoreactivity is thought to arise from the ability of DNA or RNA specific B cells to receive dual signals from the BCR and TLR9 or TLR7, respectively. The Tec kinase Btk is necessary for the production of anti-DNA antibodies in several murine models of SLE. To assess the role of Btk in the fate of DNA reactive B cells, we generated Btk-/- mice carrying the 56R anti-DNA Ig transgene on the C57BL/6 background. dsDNA specific B cells were present in 56R.Btk-/- mice, although they were not preferentially localized to the marginal zone. These cells were able to proliferate in response to large CpG DNA containing fragments that require BCR-induced internalization to access TLR9. However, anti-DNA antibodies were not observed in the serum of 56R.Btk-/- mice. A transgene expressing a low level of Btk in B cells (Btk(lo)) restored anti-DNA IgM in these mice. This correlated with partial rescue of proliferative response to BCR engagement and TLR9-induced IL-10 secretion in Btk(lo) B cells. anti-DNA IgG was not observed in 56R.Btk(lo) mice, however. This was likely due, at least in part, to a role for Btk in controlling the expression of T-bet and AID in cells stimulated with CpG DNA. Thus, Btk is required for the initial loss of tolerance to DNA and the subsequent production of pathogenic autoantibodies once tolerance is breached.

Citing Articles

Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.

Sousa B, de Almeida C, Barahona A, Lopes R, Martins-Logrado A, Cavaco M ACS Pharmacol Transl Sci. 2022; 5(11):1156-1168.

PMID: 36407952 PMC: 9667546. DOI: 10.1021/acsptsci.2c00163.


Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.

Rijvers L, van Langelaar J, Bogers L, Melief M, Koetzier S, Blok K JCI Insight. 2022; 7(16).

PMID: 35852869 PMC: 9462504. DOI: 10.1172/jci.insight.160909.


Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model.

Fukasawa T, Yoshizaki A, Ebata S, Yoshizaki-Ogawa A, Asano Y, Enomoto A Elife. 2021; 10.

PMID: 34854378 PMC: 8639144. DOI: 10.7554/eLife.67209.


Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.

Neys S, Hendriks R, Corneth O Front Cell Dev Biol. 2021; 9:668131.

PMID: 34150760 PMC: 8213343. DOI: 10.3389/fcell.2021.668131.


B Cell Aberrance in Lupus: the Ringleader and the Solution.

Nie Y, Zhao L, Zhang X Clin Rev Allergy Immunol. 2021; 62(2):301-323.

PMID: 33534064 DOI: 10.1007/s12016-020-08820-7.


References
1.
Martin F, Kearney J . Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Immunity. 2000; 12(1):39-49. DOI: 10.1016/s1074-7613(00)80157-0. View

2.
Lee K, Xu S, Wong E, Tergaonkar V, Lam K . Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J Biol Chem. 2008; 283(17):11189-98. DOI: 10.1074/jbc.M708516200. View

3.
Satterthwaite A, Witte O . The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000; 175:120-7. View

4.
Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T . Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000; 102(5):553-63. DOI: 10.1016/s0092-8674(00)00078-7. View

5.
Cariappa A, Tang M, Parng C, Nebelitskiy E, Carroll M, Georgopoulos K . The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity. 2001; 14(5):603-15. DOI: 10.1016/s1074-7613(01)00135-2. View